Cambridge Innovation Capital

TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD).

Salience Labs specializes in developing hybrid photonic-electronic chips aimed at enhancing AI data center infrastructure. The company emerged from extensive research at the University of Oxford and the University of Münster, focusing on silicon photonics to meet the increasing demands of AI workloads. Salience Labs' flagship product is an optical switch that enables all-optical networking between compute nodes, effectively addressing data movement bottlenecks. This innovation provides low-latency, high-bandwidth networking, which accelerates job completion while minimizing power consumption and costs. Additionally, the company offers high-speed multi-chip processors that integrate photonics with standard electronics, allowing for on-chip processing using photons instead of electrons. This approach significantly reduces power requirements and supports a transformation in the hardware necessary to harness the full potential of AI technologies.

Forefront RF is a fabless semiconductor company specializing in radio frequency technology. The company focuses on simplifying the design of multi-band smartphones, wearables, and Internet of Things (IoT) devices. By developing advanced radio frequency components, Forefront RF enhances the ability of these devices to receive weak signals while transmitting, thereby increasing their market reach and accessibility.

Epitopea is a transatlantic biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a novel class of tumor-specific antigens. The company utilizes a proprietary technique that integrates immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's genetic material. This approach, developed through research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal, aims to create therapies that selectively eliminate malignant cells while preserving healthy tissue. By targeting antigens that are broadly shared among patients with the same cancer type, Epitopea seeks to enhance treatment efficacy while minimizing side effects and providing durable benefits.

Nuclera specializes in providing a protein prototyping system designed to enhance drug discovery by making proteins readily accessible to researchers. The company's eProtein Discovery system enables scientists to quickly produce and evaluate proteins, thus accelerating their research efforts. Nuclera's automated platform delivers reliable, high-quality, and soluble proteins within a specified timeframe, facilitating the scale-up of protein projects. The integration of technology, including cell-free protein synthesis and digital microfluidics on smart cartridges, allows for efficient, high-throughput access to proteins. This streamlined approach supports researchers in advancing their protein projects more rapidly and effectively.

Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and in vivo models.

Riverlane is a business focused on developing quantum computing software and engineering instruments to enhance the performance of quantum computers. The company collaborates with quantum computer manufacturers to create essential hardware and software tools that address the challenges posed by unstable qubits and system defects. By designing an ultra-low latency quantum operating system, Riverlane accelerates quantum-classical hybrid algorithms, thereby advancing hardware research and development. Their algorithms are specifically engineered to optimize the utilization of the complete quantum computing stack, helping hardware partners mitigate the system errors that currently hinder the effectiveness of quantum computers. Through these innovative solutions, Riverlane aims to transform experimental quantum technologies into viable commercial products.

PragmatIC specializes in ultra-low-cost flexible electronics, specifically through the development of flexible integrated circuits (FlexICs) that are thinner than human hair. These circuits can be invisibly embedded in various objects, allowing for innovative solutions to everyday challenges that traditional electronics cannot address effectively. The company offers a FlexIC Foundry service, enabling designers to create application-specific flexible devices at a reduced cost and time compared to conventional silicon circuits, thus opening new market opportunities. Additionally, PragmatIC provides standard FlexIC products that enhance established technologies like RFID and NFC for mass-market applications, paving the way for a vast array of smart objects capable of interacting with consumers and their environments. FlexICs are produced using the company's unique FlexLogIC production system, which allows for cost-effective, high-volume manufacturing with significantly lower capital and operational costs than traditional silicon fabrication. Headquartered in Cambridge, UK, PragmatIC serves a diverse range of industries, including consumer goods, retail, healthcare, and security, with a growing global clientele.

Secondmind Ltd. is a company that specializes in developing an online software platform utilizing machine learning algorithms to facilitate artificial intelligence-based decision-making. Founded in 2016 and based in Cambridge, United Kingdom, Secondmind offers the Secondmind Decision Engine, a cloud-based platform designed to assist users in predicting, planning, managing risks, and making complex decisions efficiently. The company aims to support automotive innovators in designing cleaner vehicles and achieving sustainability goals amidst the challenges of electrification. By providing advanced tools for automotive engineers, Secondmind helps navigate the complexities of engineering design, ultimately contributing to the transition towards carbon-neutral mobility. The company has garnered backing from prominent venture funds, reflecting its commitment to advancing machine learning applications in the automotive sector.

T-Therapeutics is a biopharmaceutical company specializing in the development of engineered soluble biologics for oncological and immunological conditions. The company utilizes a proprietary T cell receptor (TCR) discovery platform, which is based on a highly humanized mouse model. This innovative approach allows T-Therapeutics to identify TCRs that target human antigens not obtainable from human samples. The TCRs bind specific pMHC targets on target cells, facilitating the recruitment of T cells to either attack cancer cells or modulate immune responses. By leveraging advanced techniques in mouse genome engineering, single cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance treatment options for patients suffering from chronic and infectious diseases while fostering a culture of creativity and collaboration within its operations.

CMR Surgical Limited, based in Cambridge, United Kingdom, specializes in the design and manufacture of medical devices tailored for minimal access surgery. The company is recognized for its Versius surgical robotic system, which enhances laparoscopic surgical procedures by making them more accessible and affordable. Founded in 2014 and originally named Cambridge Medical Robotics, CMR Surgical aims to expand the capabilities of robotic surgery, allowing a broader range of procedures to be performed. The system provides surgeons with 3D high-definition imagery and real-time feedback, significantly improving the surgical experience and outcomes for patients.

Riverlane is a business focused on developing quantum computing software and engineering instruments to enhance the performance of quantum computers. The company collaborates with quantum computer manufacturers to create essential hardware and software tools that address the challenges posed by unstable qubits and system defects. By designing an ultra-low latency quantum operating system, Riverlane accelerates quantum-classical hybrid algorithms, thereby advancing hardware research and development. Their algorithms are specifically engineered to optimize the utilization of the complete quantum computing stack, helping hardware partners mitigate the system errors that currently hinder the effectiveness of quantum computers. Through these innovative solutions, Riverlane aims to transform experimental quantum technologies into viable commercial products.

Complement Therapeutics is a preclinical stage biotechnology company focused on developing a precision medicine diagnostic platform to address chronic diseases associated with the dysregulation of the complement system. The company's innovative platform enables the stratification of patients based on their complement-activation profiles, which has the potential to enhance patient selection for clinical trials and serve as an efficacy biomarker in future studies. By offering a more tailored approach to treatment, Complement Therapeutics aims to improve medical outcomes for patients suffering from these chronic conditions.

Mosaic Therapeutics is reshaping the interface of computational and experimental medicine to power new medicines for patients.

Seldon is a developer of a machine learning deployment platform that streamlines the data science workflow for engineering teams. The company's software enhances the transition from research and development to production, significantly improving efficiency. Seldon's platform utilizes prototyping algorithms to process data and can transform machine learning models into production-ready REST and GRPC microservices. This capability allows data scientists to accelerate data interpretation and deployment. Seldon's clientele includes major enterprises across various sectors, such as technology, pharmaceuticals, automotive, finance, and retail. Additionally, the company engages in open-source projects focused on model serving, explanations, and monitoring, contributing to its widespread adoption in the industry.

Targeting pathways that modify RNA to deliver novel cancer therapeutics.

Carrick Therapeutics, Ltd., established in 2015 and headquartered in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets molecular pathways associated with aggressive and resistant forms of cancer, employing advanced mechanisms to improve treatment outcomes. By enabling the detection of predictive biomarkers, Carrick Therapeutics facilitates the initiation of targeted therapies at early stages, ultimately striving to enhance the lives of cancer patients.

Cambridge GaN Devices specializes in the development and commercialization of gallium nitride (GaN) power devices aimed at improving energy efficiency in electronic applications. The company offers a variety of GaN-based semiconductor products that enhance power conversion and minimize energy loss across different systems. These advanced devices find applications in sectors such as renewable energy, electric vehicles, and consumer electronics, supporting the shift towards more sustainable technologies. Cambridge GaN Devices focuses on creating transistors that are faster, more compact, and more efficient than traditional silicon alternatives, thereby enabling industries to utilize tailored semiconductors for critical applications. The company collaborates with industry partners to promote innovation and facilitate the integration of its technology into the power semiconductor market.

Unlikely AI is a talented group that is approaching artificial intelligence from a daring, fresh angle.

Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.

Salience Labs specializes in developing hybrid photonic-electronic chips aimed at enhancing AI data center infrastructure. The company emerged from extensive research at the University of Oxford and the University of Münster, focusing on silicon photonics to meet the increasing demands of AI workloads. Salience Labs' flagship product is an optical switch that enables all-optical networking between compute nodes, effectively addressing data movement bottlenecks. This innovation provides low-latency, high-bandwidth networking, which accelerates job completion while minimizing power consumption and costs. Additionally, the company offers high-speed multi-chip processors that integrate photonics with standard electronics, allowing for on-chip processing using photons instead of electrons. This approach significantly reduces power requirements and supports a transformation in the hardware necessary to harness the full potential of AI technologies.

Epitopea is a transatlantic biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a novel class of tumor-specific antigens. The company utilizes a proprietary technique that integrates immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's genetic material. This approach, developed through research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal, aims to create therapies that selectively eliminate malignant cells while preserving healthy tissue. By targeting antigens that are broadly shared among patients with the same cancer type, Epitopea seeks to enhance treatment efficacy while minimizing side effects and providing durable benefits.

Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and in vivo models.

Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.

PetMedix Ltd is a veterinary biopharmaceutical company based in Cambridge, United Kingdom, focused on developing therapeutic antibody drugs for pets. Founded in 2017, the company utilizes advanced scientific methods to create innovative therapies that enhance the health and well-being of companion animals. PetMedix offers specialized platforms, including the Ky9 and Felyne transgenic mouse systems, which are designed to produce high-quality, therapeutic antibodies tailored specifically for pets. By leveraging over thirty years of expertise in drug development, PetMedix aims to provide effective medical solutions that meet the unique needs of animals, ensuring they receive appropriate care and treatment.

CMR Surgical Limited, based in Cambridge, United Kingdom, specializes in the design and manufacture of medical devices tailored for minimal access surgery. The company is recognized for its Versius surgical robotic system, which enhances laparoscopic surgical procedures by making them more accessible and affordable. Founded in 2014 and originally named Cambridge Medical Robotics, CMR Surgical aims to expand the capabilities of robotic surgery, allowing a broader range of procedures to be performed. The system provides surgeons with 3D high-definition imagery and real-time feedback, significantly improving the surgical experience and outcomes for patients.

Origami specializes in developing trading and automation software for the energy sector, focusing on the management of distributed energy assets. The company aims to facilitate a transition to a greener energy world through innovative technology. Its real-time data platform incorporates advanced machine learning tools that help energy companies navigate the complexities of modern energy markets. By providing decision support systems, Origami enables clients to enhance visibility, minimize risks, and seize opportunities in evolving energy landscapes. The company's solutions are designed to optimize trading operations and improve profitability across various stages of power production and energy trading, ultimately supporting a more efficient and resilient energy ecosystem.

Sense Biodetection Limited is a molecular diagnostics company focused on improving healthcare decisions and processes by developing novel, user-centred, handheld tests in the fields of infections and oncology.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

Riverlane is a business focused on developing quantum computing software and engineering instruments to enhance the performance of quantum computers. The company collaborates with quantum computer manufacturers to create essential hardware and software tools that address the challenges posed by unstable qubits and system defects. By designing an ultra-low latency quantum operating system, Riverlane accelerates quantum-classical hybrid algorithms, thereby advancing hardware research and development. Their algorithms are specifically engineered to optimize the utilization of the complete quantum computing stack, helping hardware partners mitigate the system errors that currently hinder the effectiveness of quantum computers. Through these innovative solutions, Riverlane aims to transform experimental quantum technologies into viable commercial products.

Secondmind Ltd. is a company that specializes in developing an online software platform utilizing machine learning algorithms to facilitate artificial intelligence-based decision-making. Founded in 2016 and based in Cambridge, United Kingdom, Secondmind offers the Secondmind Decision Engine, a cloud-based platform designed to assist users in predicting, planning, managing risks, and making complex decisions efficiently. The company aims to support automotive innovators in designing cleaner vehicles and achieving sustainability goals amidst the challenges of electrification. By providing advanced tools for automotive engineers, Secondmind helps navigate the complexities of engineering design, ultimately contributing to the transition towards carbon-neutral mobility. The company has garnered backing from prominent venture funds, reflecting its commitment to advancing machine learning applications in the automotive sector.

Seldon is a developer of a machine learning deployment platform that streamlines the data science workflow for engineering teams. The company's software enhances the transition from research and development to production, significantly improving efficiency. Seldon's platform utilizes prototyping algorithms to process data and can transform machine learning models into production-ready REST and GRPC microservices. This capability allows data scientists to accelerate data interpretation and deployment. Seldon's clientele includes major enterprises across various sectors, such as technology, pharmaceuticals, automotive, finance, and retail. Additionally, the company engages in open-source projects focused on model serving, explanations, and monitoring, contributing to its widespread adoption in the industry.

Congenica is a biotechnology company based in Cambridge, Cambridgeshire, that specializes in clinical genomics. Founded in 2013, it offers a diagnostic decision support platform known as Sapientia, which integrates human DNA sequences with comprehensive clinical phenotyping. This platform enables clinicians to interpret genetic diseases more effectively by identifying mutations and filtering clinically relevant variants. By facilitating personalized medicine approaches, Congenica supports both clinicians and researchers in advancing patient care and research in the field of genetic diseases.

GeoSpock is a developer of a cloud-native database platform that specializes in geospatial big data analytics. Its flagship product, GeoSpock DB, is designed to efficiently store and fuse multiple sources of Internet of Things (IoT) data, enabling users to unlock the full value of their data while simplifying operations and reducing costs. The platform supports ANSI SQL queries and offers flexible connectivity options through JDBC/ODBC connectors, allowing integration with standard analytics tools such as Tableau, Amazon QuickSight, and Microsoft Power BI. Users can conduct deep analysis and share insights using familiar toolsets, and the database can be further integrated with proprietary applications, web services, and internal tools. Additionally, GeoSpock DB is compatible with open-source visualization libraries, providing a versatile solution for complex real-world analytics across various scale datasets.

Audiotelligence leads the world in blind audio signal separation from multi-microphone captured audio. Our AudioTelligence nD technologies greatly out-perform existing 'state-of-the art' commercially available technologies such as beam forming, spectral masking, deep neural nets, non-negative matrix factorisation and ICA.

Sense Biodetection Limited is a molecular diagnostics company focused on improving healthcare decisions and processes by developing novel, user-centred, handheld tests in the fields of infections and oncology.

CMR Surgical Limited, based in Cambridge, United Kingdom, specializes in the design and manufacture of medical devices tailored for minimal access surgery. The company is recognized for its Versius surgical robotic system, which enhances laparoscopic surgical procedures by making them more accessible and affordable. Founded in 2014 and originally named Cambridge Medical Robotics, CMR Surgical aims to expand the capabilities of robotic surgery, allowing a broader range of procedures to be performed. The system provides surgeons with 3D high-definition imagery and real-time feedback, significantly improving the surgical experience and outcomes for patients.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. The company's flagship product, PredictSURE IBD, is a diagnostic tool that evaluates patients with inflammatory bowel disease, including Crohn's disease and ulcerative colitis. This test utilizes a small blood sample to identify patients at diagnosis who are at risk of severe, relapsing disease, thereby enabling healthcare providers to recommend early biologic therapy to those who would benefit most. By providing crucial prognostic information, PredictImmune aims to enhance treatment decision-making for physicians and improve outcomes for patients suffering from these conditions. The company's research is rooted in leading studies from Cambridge University, reflecting its commitment to advancing personalized medicine in the field of inflammatory bowel disease.

Riverlane is a business focused on developing quantum computing software and engineering instruments to enhance the performance of quantum computers. The company collaborates with quantum computer manufacturers to create essential hardware and software tools that address the challenges posed by unstable qubits and system defects. By designing an ultra-low latency quantum operating system, Riverlane accelerates quantum-classical hybrid algorithms, thereby advancing hardware research and development. Their algorithms are specifically engineered to optimize the utilization of the complete quantum computing stack, helping hardware partners mitigate the system errors that currently hinder the effectiveness of quantum computers. Through these innovative solutions, Riverlane aims to transform experimental quantum technologies into viable commercial products.

Audio Analytic Ltd. is a developer of sound recognition software based in Cambridge, United Kingdom, with an additional office in San Francisco, California. Founded in 2008, the company specializes in creating embedded software platforms, including ai3™ and ai3-nano™, designed to enhance consumer products with advanced sound detection and classification capabilities. Its technology enables devices such as smart speakers, video doorbells, smartphones, and true wireless earbuds to gain a greater understanding of audio context, thereby improving user experiences. Audio Analytic offers a range of products, including sound classification software and tools for loudness detection, which are licensed to original equipment manufacturers and chip providers within the consumer electronics and entertainment sectors. The company aims to empower technology by integrating an intelligent sense of hearing, allowing devices to respond more effectively to their environments.

Targeting pathways that modify RNA to deliver novel cancer therapeutics.

Secondmind Ltd. is a company that specializes in developing an online software platform utilizing machine learning algorithms to facilitate artificial intelligence-based decision-making. Founded in 2016 and based in Cambridge, United Kingdom, Secondmind offers the Secondmind Decision Engine, a cloud-based platform designed to assist users in predicting, planning, managing risks, and making complex decisions efficiently. The company aims to support automotive innovators in designing cleaner vehicles and achieving sustainability goals amidst the challenges of electrification. By providing advanced tools for automotive engineers, Secondmind helps navigate the complexities of engineering design, ultimately contributing to the transition towards carbon-neutral mobility. The company has garnered backing from prominent venture funds, reflecting its commitment to advancing machine learning applications in the automotive sector.

PolyProx Therapeutics is developer of a novel class of drug intended to provide new therapies for cancer treatment. The company's drug will use novel engineered protein that is able to selectively target tumour cells and trigger natural degradation machinery within the cell, enabling cancer patients to benefit from the treatment that targets and remove disease-causing proteins.

Cytora is a London-based company founded in 2014 that specializes in a configurable platform designed for commercial insurers to enhance their risk processing capabilities. The platform digitizes incoming risks and enriches them with both internal and external data sources. It evaluates these risks using various rules related to appetite and priority before directing them to downstream systems for either automated or manual underwriting. By leveraging artificial intelligence, Cytora's platform learns the patterns of different risks and loss outcomes over time, allowing insurers to assign a rank, score, and price to each property and organization. This approach aims to improve risk selection, pricing accuracy, and overall efficiency in underwriting processes.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. Inivata's innovative approach utilizes TAm-Seq technology to detect and analyze genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples, known as liquid biopsies. This method revolutionizes cancer detection and monitoring by providing a less invasive alternative to traditional biopsies. The company's focus is on enabling clinicians to make more informed treatment decisions by monitoring response to therapies and detecting potential relapses in cancer patients. Inivata has also formed a strategic collaboration with NeoGenomics, Inc.

PragmatIC specializes in ultra-low-cost flexible electronics, specifically through the development of flexible integrated circuits (FlexICs) that are thinner than human hair. These circuits can be invisibly embedded in various objects, allowing for innovative solutions to everyday challenges that traditional electronics cannot address effectively. The company offers a FlexIC Foundry service, enabling designers to create application-specific flexible devices at a reduced cost and time compared to conventional silicon circuits, thus opening new market opportunities. Additionally, PragmatIC provides standard FlexIC products that enhance established technologies like RFID and NFC for mass-market applications, paving the way for a vast array of smart objects capable of interacting with consumers and their environments. FlexICs are produced using the company's unique FlexLogIC production system, which allows for cost-effective, high-volume manufacturing with significantly lower capital and operational costs than traditional silicon fabrication. Headquartered in Cambridge, UK, PragmatIC serves a diverse range of industries, including consumer goods, retail, healthcare, and security, with a growing global clientele.

Imagen Ltd specializes in media archive management solutions, providing tools for content owners to manage, search, and distribute their media libraries effectively. Its offerings include Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based platform for video and image management; and Orbital, a system designed for compliance recording. The company serves a diverse clientele, including the Ministry of Defence, The Police, the BBC, ITN, the Imperial War Museum, British Telecom, and British Pathe. Founded in 1991 and based in Willingham, United Kingdom, Imagen was previously known as Cambridge Imaging Systems Limited before rebranding in August 2015. The company's modular enterprise video platform supports businesses of all sizes in monetizing their media archives.

MORPHOGEN-IX Limited is a drug discovery company founded in 2015 by Index Ventures to develop bone morphogenetic proteins as a novel therapy for the treatment for pulmonary arterial hypertension Pulmonary arterial hypertension is a severe and life-limiting disease that affects the blood vessels in the lungs, leading to heart failure, and leaves sufferers feeling breathless and exhausted. Current treatments mainly target symptoms and the prognosis remains poor. The only effective cure is transplantation of the lungs or heart and lungs, which has associated risks and complications. Compromised bone morphogenetic protein (BMP) receptor type II (BMPR-II) signalling in endothelial cells plays a pivotal role in the pathobiology PAH, as identified from human genetic studies. BMP9 and 10 represent circulating ligands that selectively bind and activate BMPR-II receptor complexes on endothelial cells. Administration of exogenous BMP9 has been shown to augment endothelial BMPR-II signalling and reverse PAH in several rodent models of disease. Our goal is to explore the potential of BMP9 and BMP10 as potential therapies for PAH. The company follows the semi-virtual model with a hub based in Cambridge, UK. The company founders are experts in the field of PAH and BMPs. The team is staffed with experienced drug discovery professionals to direct an out-sourced development program. This model ensures maximum capital efficiency without sacrificing quality.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

CEDAR Audio is the world's only company dedicated solely to audio restoration and speech enhancement for film, post, TV and radio broadcast, CD and DVD mastering, libraries and archives, and for audio forensic investigation. Established in 1988 following five years of research funded by the British Library National Sound Archive, CEDAR Audio is based in Cambridge, UK, and retains strong academic links with Cambridge University, itself one of the world's leading centres for digital signal processing research. The company currently numbers two Cambridge University Professors and a Director of Studies among its Directors, further strengthening its ability to remain at the forefront of its field. CEDAR Audio is committed to furthering the science and technology of audio restoration and speech enhancements in all its forms. It not only manufactures many of the leading products in these fields, but actively pursues research into new techniques in each of them. The company also places a premium on the highest standards of customer support, and has earned numerous accolades in this area.

Audiotelligence leads the world in blind audio signal separation from multi-microphone captured audio. Our AudioTelligence nD technologies greatly out-perform existing 'state-of-the art' commercially available technologies such as beam forming, spectral masking, deep neural nets, non-negative matrix factorisation and ICA.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

Nstream, founded in 2015 and based in California, specializes in advanced analytics software that processes edge data in real-time. The company's flagship product, SWIM EDX, transforms streaming data into actionable insights and predictions, addressing the complexities associated with big data. Nstream offers solutions tailored for a diverse range of clients, including original equipment manufacturers, service providers, enterprises, and Internet of Things (IoT) vendors. Its platform combines edge computing, machine learning, and self-training digital twins within a unique mesh architecture. Additionally, Nstream provides Swim Continuum, an open-core, enterprise-grade platform designed for building and managing continuous intelligence applications at scale. This platform enhances situational awareness and decision-making by delivering precise, relevant data through a stateful architecture that minimizes latency and optimizes performance for high-frequency data analytics. By integrating seamlessly with existing enterprise systems, Nstream enables organizations to improve productivity, reduce operational costs, and gain deeper insights into their business operations.

Undo Ltd. specializes in developing advanced debugging tools aimed at enhancing software development processes for professionals such as developers, software architects, and product managers. The company offers innovative solutions like LiveRecorder, which records and replays software execution, allowing users to identify and resolve programming errors effectively. Additionally, UndoDB serves as an interactive reversible debugger for C/C++ applications on Linux and Android platforms. By employing time travel debugging technology, Undo enables developers to gain insights into complex code, facilitating the diagnosis of new regressions, legacy bugs, and flaky tests prior to customer impact. The company primarily caters to industries including data management, networking, electronic design automation, and finance. Founded in 2005, Undo Ltd. operates from its headquarters in Cambridge, United Kingdom, and maintains an additional office in San Francisco, California.

CMR Surgical Limited, based in Cambridge, United Kingdom, specializes in the design and manufacture of medical devices tailored for minimal access surgery. The company is recognized for its Versius surgical robotic system, which enhances laparoscopic surgical procedures by making them more accessible and affordable. Founded in 2014 and originally named Cambridge Medical Robotics, CMR Surgical aims to expand the capabilities of robotic surgery, allowing a broader range of procedures to be performed. The system provides surgeons with 3D high-definition imagery and real-time feedback, significantly improving the surgical experience and outcomes for patients.

Origami specializes in developing trading and automation software for the energy sector, focusing on the management of distributed energy assets. The company aims to facilitate a transition to a greener energy world through innovative technology. Its real-time data platform incorporates advanced machine learning tools that help energy companies navigate the complexities of modern energy markets. By providing decision support systems, Origami enables clients to enhance visibility, minimize risks, and seize opportunities in evolving energy landscapes. The company's solutions are designed to optimize trading operations and improve profitability across various stages of power production and energy trading, ultimately supporting a more efficient and resilient energy ecosystem.

GeoSpock is a developer of a cloud-native database platform that specializes in geospatial big data analytics. Its flagship product, GeoSpock DB, is designed to efficiently store and fuse multiple sources of Internet of Things (IoT) data, enabling users to unlock the full value of their data while simplifying operations and reducing costs. The platform supports ANSI SQL queries and offers flexible connectivity options through JDBC/ODBC connectors, allowing integration with standard analytics tools such as Tableau, Amazon QuickSight, and Microsoft Power BI. Users can conduct deep analysis and share insights using familiar toolsets, and the database can be further integrated with proprietary applications, web services, and internal tools. Additionally, GeoSpock DB is compatible with open-source visualization libraries, providing a versatile solution for complex real-world analytics across various scale datasets.

Cytora is a London-based company founded in 2014 that specializes in a configurable platform designed for commercial insurers to enhance their risk processing capabilities. The platform digitizes incoming risks and enriches them with both internal and external data sources. It evaluates these risks using various rules related to appetite and priority before directing them to downstream systems for either automated or manual underwriting. By leveraging artificial intelligence, Cytora's platform learns the patterns of different risks and loss outcomes over time, allowing insurers to assign a rank, score, and price to each property and organization. This approach aims to improve risk selection, pricing accuracy, and overall efficiency in underwriting processes.

CMR Surgical Limited, based in Cambridge, United Kingdom, specializes in the design and manufacture of medical devices tailored for minimal access surgery. The company is recognized for its Versius surgical robotic system, which enhances laparoscopic surgical procedures by making them more accessible and affordable. Founded in 2014 and originally named Cambridge Medical Robotics, CMR Surgical aims to expand the capabilities of robotic surgery, allowing a broader range of procedures to be performed. The system provides surgeons with 3D high-definition imagery and real-time feedback, significantly improving the surgical experience and outcomes for patients.

Secondmind Ltd. is a company that specializes in developing an online software platform utilizing machine learning algorithms to facilitate artificial intelligence-based decision-making. Founded in 2016 and based in Cambridge, United Kingdom, Secondmind offers the Secondmind Decision Engine, a cloud-based platform designed to assist users in predicting, planning, managing risks, and making complex decisions efficiently. The company aims to support automotive innovators in designing cleaner vehicles and achieving sustainability goals amidst the challenges of electrification. By providing advanced tools for automotive engineers, Secondmind helps navigate the complexities of engineering design, ultimately contributing to the transition towards carbon-neutral mobility. The company has garnered backing from prominent venture funds, reflecting its commitment to advancing machine learning applications in the automotive sector.

Z Factor Limited is a drug discovery company established in 2015, focusing on developing therapeutic agents for alpha-1-antitrypsin deficiency. Founded through a collaboration between Index Ventures and the University of Cambridge, the company aims to design innovative treatments that correct the misfolding of the Z variant of alpha-1-antitrypsin. This condition currently has limited treatment options, primarily relying on lung or liver transplantation and augmentation therapy. Z Factor's mission addresses a significant unmet medical need by working to create effective alternatives for patients suffering from this deficiency.

Congenica is a biotechnology company based in Cambridge, Cambridgeshire, that specializes in clinical genomics. Founded in 2013, it offers a diagnostic decision support platform known as Sapientia, which integrates human DNA sequences with comprehensive clinical phenotyping. This platform enables clinicians to interpret genetic diseases more effectively by identifying mutations and filtering clinically relevant variants. By facilitating personalized medicine approaches, Congenica supports both clinicians and researchers in advancing patient care and research in the field of genetic diseases.

Audio Analytic Ltd. is a developer of sound recognition software based in Cambridge, United Kingdom, with an additional office in San Francisco, California. Founded in 2008, the company specializes in creating embedded software platforms, including ai3™ and ai3-nano™, designed to enhance consumer products with advanced sound detection and classification capabilities. Its technology enables devices such as smart speakers, video doorbells, smartphones, and true wireless earbuds to gain a greater understanding of audio context, thereby improving user experiences. Audio Analytic offers a range of products, including sound classification software and tools for loudness detection, which are licensed to original equipment manufacturers and chip providers within the consumer electronics and entertainment sectors. The company aims to empower technology by integrating an intelligent sense of hearing, allowing devices to respond more effectively to their environments.

Exvastat is a preclinical-stage pharmaceutical company founded in 2016, focused on developing treatments for acute respiratory distress syndrome (ARDS). The company is working on a repurposed drug that is already marketed for other indications, aiming to address the critical need for effective therapies in ARDS. This innovative treatment has the potential to significantly lower mortality rates and debilitating complications associated with the syndrome, while also reducing healthcare costs for providers managing critically ill patients. By targeting the underlying causes of pulmonary edema, Exvastat seeks to improve patient outcomes and enhance the standard of care in respiratory distress scenarios.

Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and in vivo models.

Imagen Ltd specializes in media archive management solutions, providing tools for content owners to manage, search, and distribute their media libraries effectively. Its offerings include Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based platform for video and image management; and Orbital, a system designed for compliance recording. The company serves a diverse clientele, including the Ministry of Defence, The Police, the BBC, ITN, the Imperial War Museum, British Telecom, and British Pathe. Founded in 1991 and based in Willingham, United Kingdom, Imagen was previously known as Cambridge Imaging Systems Limited before rebranding in August 2015. The company's modular enterprise video platform supports businesses of all sizes in monetizing their media archives.

Undo Ltd. specializes in developing advanced debugging tools aimed at enhancing software development processes for professionals such as developers, software architects, and product managers. The company offers innovative solutions like LiveRecorder, which records and replays software execution, allowing users to identify and resolve programming errors effectively. Additionally, UndoDB serves as an interactive reversible debugger for C/C++ applications on Linux and Android platforms. By employing time travel debugging technology, Undo enables developers to gain insights into complex code, facilitating the diagnosis of new regressions, legacy bugs, and flaky tests prior to customer impact. The company primarily caters to industries including data management, networking, electronic design automation, and finance. Founded in 2005, Undo Ltd. operates from its headquarters in Cambridge, United Kingdom, and maintains an additional office in San Francisco, California.

PragmatIC specializes in ultra-low-cost flexible electronics, specifically through the development of flexible integrated circuits (FlexICs) that are thinner than human hair. These circuits can be invisibly embedded in various objects, allowing for innovative solutions to everyday challenges that traditional electronics cannot address effectively. The company offers a FlexIC Foundry service, enabling designers to create application-specific flexible devices at a reduced cost and time compared to conventional silicon circuits, thus opening new market opportunities. Additionally, PragmatIC provides standard FlexIC products that enhance established technologies like RFID and NFC for mass-market applications, paving the way for a vast array of smart objects capable of interacting with consumers and their environments. FlexICs are produced using the company's unique FlexLogIC production system, which allows for cost-effective, high-volume manufacturing with significantly lower capital and operational costs than traditional silicon fabrication. Headquartered in Cambridge, UK, PragmatIC serves a diverse range of industries, including consumer goods, retail, healthcare, and security, with a growing global clientele.

Carrick Therapeutics, Ltd., established in 2015 and headquartered in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets molecular pathways associated with aggressive and resistant forms of cancer, employing advanced mechanisms to improve treatment outcomes. By enabling the detection of predictive biomarkers, Carrick Therapeutics facilitates the initiation of targeted therapies at early stages, ultimately striving to enhance the lives of cancer patients.

PervasID Limited is a company based in Cambridge, United Kingdom, that specializes in the development of wide area passive RFID systems. Founded in 2011, PervasID focuses on providing location capabilities based on the EPC Class1 Gen2 standard. The company emerged from research conducted in the Engineering Department at the University of Cambridge and has since successfully deployed its technology in various field trials. PervasID's innovative RFID tracking system is designed to serve multiple industries, including retail, healthcare, supply chain and logistics, and aviation. Utilizing patented technology, the system employs fixed ultra-high frequency RFID to detect passive tags over long ranges with high accuracy, enabling organizations to enhance visibility into goods, assets, and personnel, thereby streamlining operational processes.

Fluidic Analytics Limited, founded in 2013 as a spin-out from the University of Cambridge, specializes in the design, development, and manufacturing of advanced analytical tools for protein characterization. The company focuses on creating innovative products that facilitate in-solution sizing and quantification of proteins, with offerings such as Fluidity One and Fluidity One-W, which enable high sensitivity analysis of protein size and interaction kinetics. These tools are essential for a variety of applications, including assessing protein quality, interactions, and aggregation. Fluidic Analytics serves a diverse clientele, including scientists, clinics, and healthcare providers, aiming to enhance the understanding of protein behavior and its implications in biological processes. By combining cutting-edge technology with a commitment to accessibility and user data ownership, the company aspires to transform the field of protein science, paralleling the revolutionary impact of advancements in DNA sequencing.

CMR Surgical Limited, based in Cambridge, United Kingdom, specializes in the design and manufacture of medical devices tailored for minimal access surgery. The company is recognized for its Versius surgical robotic system, which enhances laparoscopic surgical procedures by making them more accessible and affordable. Founded in 2014 and originally named Cambridge Medical Robotics, CMR Surgical aims to expand the capabilities of robotic surgery, allowing a broader range of procedures to be performed. The system provides surgeons with 3D high-definition imagery and real-time feedback, significantly improving the surgical experience and outcomes for patients.

Targeting pathways that modify RNA to deliver novel cancer therapeutics.

Origami specializes in developing trading and automation software for the energy sector, focusing on the management of distributed energy assets. The company aims to facilitate a transition to a greener energy world through innovative technology. Its real-time data platform incorporates advanced machine learning tools that help energy companies navigate the complexities of modern energy markets. By providing decision support systems, Origami enables clients to enhance visibility, minimize risks, and seize opportunities in evolving energy landscapes. The company's solutions are designed to optimize trading operations and improve profitability across various stages of power production and energy trading, ultimately supporting a more efficient and resilient energy ecosystem.

Audio Analytic Ltd. is a developer of sound recognition software based in Cambridge, United Kingdom, with an additional office in San Francisco, California. Founded in 2008, the company specializes in creating embedded software platforms, including ai3™ and ai3-nano™, designed to enhance consumer products with advanced sound detection and classification capabilities. Its technology enables devices such as smart speakers, video doorbells, smartphones, and true wireless earbuds to gain a greater understanding of audio context, thereby improving user experiences. Audio Analytic offers a range of products, including sound classification software and tools for loudness detection, which are licensed to original equipment manufacturers and chip providers within the consumer electronics and entertainment sectors. The company aims to empower technology by integrating an intelligent sense of hearing, allowing devices to respond more effectively to their environments.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. Inivata's innovative approach utilizes TAm-Seq technology to detect and analyze genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples, known as liquid biopsies. This method revolutionizes cancer detection and monitoring by providing a less invasive alternative to traditional biopsies. The company's focus is on enabling clinicians to make more informed treatment decisions by monitoring response to therapies and detecting potential relapses in cancer patients. Inivata has also formed a strategic collaboration with NeoGenomics, Inc.

MORPHOGEN-IX Limited is a drug discovery company founded in 2015 by Index Ventures to develop bone morphogenetic proteins as a novel therapy for the treatment for pulmonary arterial hypertension Pulmonary arterial hypertension is a severe and life-limiting disease that affects the blood vessels in the lungs, leading to heart failure, and leaves sufferers feeling breathless and exhausted. Current treatments mainly target symptoms and the prognosis remains poor. The only effective cure is transplantation of the lungs or heart and lungs, which has associated risks and complications. Compromised bone morphogenetic protein (BMP) receptor type II (BMPR-II) signalling in endothelial cells plays a pivotal role in the pathobiology PAH, as identified from human genetic studies. BMP9 and 10 represent circulating ligands that selectively bind and activate BMPR-II receptor complexes on endothelial cells. Administration of exogenous BMP9 has been shown to augment endothelial BMPR-II signalling and reverse PAH in several rodent models of disease. Our goal is to explore the potential of BMP9 and BMP10 as potential therapies for PAH. The company follows the semi-virtual model with a hub based in Cambridge, UK. The company founders are experts in the field of PAH and BMPs. The team is staffed with experienced drug discovery professionals to direct an out-sourced development program. This model ensures maximum capital efficiency without sacrificing quality.

Jukedeck is developing an artificially intelligent music composer - a system that writes original music completely on its own. Jukedeck is based on state-of-the-art technology they are building that brings artificial intelligence to music composition and production. They are training deep neural networks to understand music composition at a granular level, so that they can build tools to aid creativity.

GeoSpock is a developer of a cloud-native database platform that specializes in geospatial big data analytics. Its flagship product, GeoSpock DB, is designed to efficiently store and fuse multiple sources of Internet of Things (IoT) data, enabling users to unlock the full value of their data while simplifying operations and reducing costs. The platform supports ANSI SQL queries and offers flexible connectivity options through JDBC/ODBC connectors, allowing integration with standard analytics tools such as Tableau, Amazon QuickSight, and Microsoft Power BI. Users can conduct deep analysis and share insights using familiar toolsets, and the database can be further integrated with proprietary applications, web services, and internal tools. Additionally, GeoSpock DB is compatible with open-source visualization libraries, providing a versatile solution for complex real-world analytics across various scale datasets.

Targeting pathways that modify RNA to deliver novel cancer therapeutics.

Imagen Ltd specializes in media archive management solutions, providing tools for content owners to manage, search, and distribute their media libraries effectively. Its offerings include Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based platform for video and image management; and Orbital, a system designed for compliance recording. The company serves a diverse clientele, including the Ministry of Defence, The Police, the BBC, ITN, the Imperial War Museum, British Telecom, and British Pathe. Founded in 1991 and based in Willingham, United Kingdom, Imagen was previously known as Cambridge Imaging Systems Limited before rebranding in August 2015. The company's modular enterprise video platform supports businesses of all sizes in monetizing their media archives.

Abcodia Ltd. is a biotechnology company that specializes in the discovery and validation of molecular biomarkers to enhance disease diagnosis and screening, particularly for cancer. The company offers the Roca Test, which is designed for early detection of ovarian cancer, serving clients across various states in the United States as well as in the United Kingdom. Abcodia leverages a unique longitudinal serum biobank and collaborates with institutions like University College London and major diagnostic firms to facilitate comprehensive diagnostic development. Founded in 2010, Abcodia is headquartered in London, United Kingdom.

Undo Ltd. specializes in developing advanced debugging tools aimed at enhancing software development processes for professionals such as developers, software architects, and product managers. The company offers innovative solutions like LiveRecorder, which records and replays software execution, allowing users to identify and resolve programming errors effectively. Additionally, UndoDB serves as an interactive reversible debugger for C/C++ applications on Linux and Android platforms. By employing time travel debugging technology, Undo enables developers to gain insights into complex code, facilitating the diagnosis of new regressions, legacy bugs, and flaky tests prior to customer impact. The company primarily caters to industries including data management, networking, electronic design automation, and finance. Founded in 2005, Undo Ltd. operates from its headquarters in Cambridge, United Kingdom, and maintains an additional office in San Francisco, California.

Congenica is a biotechnology company based in Cambridge, Cambridgeshire, that specializes in clinical genomics. Founded in 2013, it offers a diagnostic decision support platform known as Sapientia, which integrates human DNA sequences with comprehensive clinical phenotyping. This platform enables clinicians to interpret genetic diseases more effectively by identifying mutations and filtering clinically relevant variants. By facilitating personalized medicine approaches, Congenica supports both clinicians and researchers in advancing patient care and research in the field of genetic diseases.

PragmatIC specializes in ultra-low-cost flexible electronics, specifically through the development of flexible integrated circuits (FlexICs) that are thinner than human hair. These circuits can be invisibly embedded in various objects, allowing for innovative solutions to everyday challenges that traditional electronics cannot address effectively. The company offers a FlexIC Foundry service, enabling designers to create application-specific flexible devices at a reduced cost and time compared to conventional silicon circuits, thus opening new market opportunities. Additionally, PragmatIC provides standard FlexIC products that enhance established technologies like RFID and NFC for mass-market applications, paving the way for a vast array of smart objects capable of interacting with consumers and their environments. FlexICs are produced using the company's unique FlexLogIC production system, which allows for cost-effective, high-volume manufacturing with significantly lower capital and operational costs than traditional silicon fabrication. Headquartered in Cambridge, UK, PragmatIC serves a diverse range of industries, including consumer goods, retail, healthcare, and security, with a growing global clientele.

Congenica is a biotechnology company based in Cambridge, Cambridgeshire, that specializes in clinical genomics. Founded in 2013, it offers a diagnostic decision support platform known as Sapientia, which integrates human DNA sequences with comprehensive clinical phenotyping. This platform enables clinicians to interpret genetic diseases more effectively by identifying mutations and filtering clinically relevant variants. By facilitating personalized medicine approaches, Congenica supports both clinicians and researchers in advancing patient care and research in the field of genetic diseases.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. Inivata's innovative approach utilizes TAm-Seq technology to detect and analyze genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples, known as liquid biopsies. This method revolutionizes cancer detection and monitoring by providing a less invasive alternative to traditional biopsies. The company's focus is on enabling clinicians to make more informed treatment decisions by monitoring response to therapies and detecting potential relapses in cancer patients. Inivata has also formed a strategic collaboration with NeoGenomics, Inc.

Jukedeck is developing an artificially intelligent music composer - a system that writes original music completely on its own. Jukedeck is based on state-of-the-art technology they are building that brings artificial intelligence to music composition and production. They are training deep neural networks to understand music composition at a granular level, so that they can build tools to aid creativity.

Origami specializes in developing trading and automation software for the energy sector, focusing on the management of distributed energy assets. The company aims to facilitate a transition to a greener energy world through innovative technology. Its real-time data platform incorporates advanced machine learning tools that help energy companies navigate the complexities of modern energy markets. By providing decision support systems, Origami enables clients to enhance visibility, minimize risks, and seize opportunities in evolving energy landscapes. The company's solutions are designed to optimize trading operations and improve profitability across various stages of power production and energy trading, ultimately supporting a more efficient and resilient energy ecosystem.

Imagen Ltd specializes in media archive management solutions, providing tools for content owners to manage, search, and distribute their media libraries effectively. Its offerings include Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based platform for video and image management; and Orbital, a system designed for compliance recording. The company serves a diverse clientele, including the Ministry of Defence, The Police, the BBC, ITN, the Imperial War Museum, British Telecom, and British Pathe. Founded in 1991 and based in Willingham, United Kingdom, Imagen was previously known as Cambridge Imaging Systems Limited before rebranding in August 2015. The company's modular enterprise video platform supports businesses of all sizes in monetizing their media archives.